FOXA1 protein expression and survival of breast cancer patients

Forkhead box protein A1 (FOXA1) is pioneer factor has a dual role either as growth stimulator or a repressor and the significance role of this protein as a prognostic biomarker still controversial, so the aim of this study was to identify the precise role of FOXA1 protein expression in prediction of BC patients outcome and recurrence of BC by immunohistochemical (IHC) staning method. In this study, seventy three tissues samples embedded in wax block were taken from BC patients with (52.71+11.55) years who had surgery between 2014-2020 and thirty eight of normal (non tumoral) breast tissues samples with (54.17+10.84) years as a control group. Negative FOXA1 expression increased significantly in patients with recurrence BC (P=0.006), BC patients with good prognosis and moderate prognosis have a significant correlation with positive FOXA1 expression (P=0.018). Overall survival (OS) was 82.74% in patients with positive expression of FOXA1 which is longer than OS in BC patients with negative expression of FOXA1 (61.31%), (P=0.001). Disease free survival (DFS) was 81.36% in BC patients with positive expression of FOXA1 which also longer than in BC patients with negative expression of FOXA1 (59.8%) (p=0.0001). FOXA1 was a good prognostic marker for survival of BC patients.